Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OYSTER POINT PHARMA, INC.

(OYST)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Oyster Point Pharma, Inc.
Oyster Point Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The Company's lead product candidate is OC-01 (varenicline) nasal spray, a selective nicotinic acetylcholine receptor (nAChR) agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01's is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the TPP and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

Number of employees : 62 people.
Managers
Name Title Age Since
Jeffrey A. Nau, Dr. President, Chief Executive Officer & Director 46 2017
Daniel Lochner Chief Financial Officer 39 2019
Marian Macsai, Dr. Chief Medical Officer & Head-Medical Affairs - 2020
Eric Carlson, Dr. Chief Scientific Officer - 2020
George Donato Senior Vice President-Operations & CMC - -
Raegan McClain Chief Compliance Officer - 2021
William J. Link, Dr. Independent Director 74 2015
Clare R. Ozawa, Dr. Independent Director 47 2019
Benjamin Tsai Independent Director 41 2019
Aimee S. Weisner Independent Director 52 2019
Members of the board
Name Title Age Since
Donald J. Santel Non-Executive Chairman 60 2021
Jeffrey A. Nau, Dr. President, Chief Executive Officer & Director 46 2017
Ali Behbahani, Dr. Director 45 2021
William J. Link, Dr. Independent Director 74 2015
Mark A. Murray Director 62 2019
Clare R. Ozawa, Dr. Independent Director 47 2019
Benjamin Tsai Independent Director 41 2019
Aimee S. Weisner Independent Director 52 2019
Michael G. Atieh Independent Director 67 2020
George Eliades, Dr. Independent Director - 2021
Shareholders
NameEquities%
NEA Management Co. LLC 5,925,287 22.6%
Versant Venture Management LLC 3,657,618 14.0%
Invus Financial Advisors LLC 2,768,586 10.6%
Point72 Asset Management LP 2,297,761 8.78%
RTW Investments LP 1,861,209 7.11%
Kohlberg Kravis Roberts & Co. LP 1,039,622 3.97%
VV Manager LLC 640,070 2.45%
The Vanguard Group, Inc. 614,283 2.35%
Wellington Management Co. LLP 594,311 2.27%
First Manhattan Co. 444,489 1.70%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Oyster Point Pharma, Inc.